These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 28315555)

  • 1. Checkpoint Inhibitors: Common Immune-Related Adverse Events and Their Management
.
    Gordon R; Kasler MK; Stasi K; Shames Y; Errante M; Ciccolini K; Skripnik Lucas A; Raasch P; Fischer-Cartlidge E
    Clin J Oncol Nurs; 2017 Apr; 21(2 Suppl):45-52. PubMed ID: 28315555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicity Management: Development of a Novel and Immune-Mediated Adverse Events Algorithm
.
    Mistry H; Forbes SG; Fowler N
    Clin J Oncol Nurs; 2017 Apr; 21(2 Suppl):53-59. PubMed ID: 28315558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of skin adverse events associated with immune checkpoint inhibitors in patients with melanoma: A nursing perspective.
    Thebeau M; Rubin K; Hofmann M; Grimm J; Weinstein A; Choi JN
    J Am Assoc Nurse Pract; 2017 May; 29(5):294-303. PubMed ID: 28436601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durvalumab Immunotherapy: Nursing Management of Immune-Related Adverse Events During the Journey of Patients With Stage III Non-Small Cell Lung Cancer.
    Davies M; Duffield E
    Clin J Oncol Nurs; 2020 Jun; 24(3):277-283. PubMed ID: 32441679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypophysitis: Nursing Management of Immune-Related Adverse Events
.
    Vazquez A
    Clin J Oncol Nurs; 2017 Apr; 21(2):154-156. PubMed ID: 28315541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer Immunotherapy: An Evidence-Based Overview and Implications for Practice.
    Bayer V; Amaya B; Baniewicz D; Callahan C; Marsh L; McCoy AS
    Clin J Oncol Nurs; 2017 Apr; 21(2 Suppl):13-21. PubMed ID: 28315552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute and Long-term Adverse Events Associated With Checkpoint Blockade.
    Davies M
    Semin Oncol Nurs; 2019 Oct; 35(5):150926. PubMed ID: 31514992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update.
    Nagai H; Muto M
    Int J Clin Oncol; 2018 Jun; 23(3):410-420. PubMed ID: 29516216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.
    Champiat S; Lambotte O; Barreau E; Belkhir R; Berdelou A; Carbonnel F; Cauquil C; Chanson P; Collins M; Durrbach A; Ederhy S; Feuillet S; François H; Lazarovici J; Le Pavec J; De Martin E; Mateus C; Michot JM; Samuel D; Soria JC; Robert C; Eggermont A; Marabelle A
    Ann Oncol; 2016 Apr; 27(4):559-74. PubMed ID: 26715621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on New Therapies With Immune Checkpoint Inhibitors.
    Peterson JJ; Steele-Moses SK
    Clin J Oncol Nurs; 2016 Aug; 20(4):405-10. PubMed ID: 27441513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Avelumab Immunotherapy: Management of Adverse Events Associated With New Treatment for Merkel Cell Carcinoma.
    Ugolini H; Bryan J; Hennessy M; Kaufman HL; D'Angelo S
    Clin J Oncol Nurs; 2019 Feb; 23(1):E1-E9. PubMed ID: 30682006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding Immune Checkpoint Inhibitors for Effective Patient Care.
    Rubin KM
    Clin J Oncol Nurs; 2015 Dec; 19(6):709-17. PubMed ID: 26583635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy Summit: Proceedings and Identified Priorities for Safe Administration and Care.
    Galioto M; Mucenski J
    Clin J Oncol Nurs; 2019 Jun; 23(3):E60-E65. PubMed ID: 31099794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors.
    Kottschade LA
    Curr Oncol Rep; 2018 Mar; 20(3):24. PubMed ID: 29511902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
    La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
    Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Future of Immunotherapy in the Treatment of Cancer.
    Kottschade LA
    Semin Oncol Nurs; 2019 Oct; 35(5):150934. PubMed ID: 31477413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A large scale meta analysis identifies common adverse events with checkpoint inhibitors vs chemotherapy in melanoma patients.
    Zhang R; Li X; You Z; Jiang L; Weng Y; Shi Q; Du L; Yan S
    Int Immunopharmacol; 2019 Sep; 74():105691. PubMed ID: 31252248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy.
    Bronstein Y; Ng CS; Hwu P; Hwu WJ
    AJR Am J Roentgenol; 2011 Dec; 197(6):W992-W1000. PubMed ID: 22109345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge.
    Kostine M; Chiche L; Lazaro E; Halfon P; Charpin C; Arniaud D; Retornaz F; Blanco P; Jourde-Chiche N; Richez C; Stavris C
    Rev Med Interne; 2017 Aug; 38(8):513-525. PubMed ID: 28214182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Management of adverse events in immune oncology - Practical aspects of immune-related adverse events during immune oncological treatment].
    Reinmuth N; Bitzer M; Deschler-Baier B; Fischer JR; Kuon J; Leipe J; Rawluk J; Schulz C; Heußel CP; Schultheiß M
    Dtsch Med Wochenschr; 2019 Mar; 144(5):346-353. PubMed ID: 30699440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.